Insights on the Ophthalmic Equipment Global Market to 2027

Featuring Alcon, Canon Medical Systems and Diamatrix Among Others

The “Ophthalmic Equipment Market Research Report by Product, by End-user, by Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.

The Global Ophthalmic Equipment Market size was estimated at USD 48.05 billion in 2020, is expected to reach USD 50.85 billion in 2021, and is projected to grow at a CAGR of 6.19% to reach USD 73.17 billion by 2027.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ophthalmic Equipment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Ophthalmic Equipment Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Ophthalmic Equipment Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Ophthalmic Equipment Market?

4. What is the competitive strategic window for opportunities in the Global Ophthalmic Equipment Market?

5. What are the technology trends and regulatory frameworks in the Global Ophthalmic Equipment Market?

6. What is the market share of the leading vendors in the Global Ophthalmic Equipment Market?

7. What modes and strategic moves are considered suitable for entering the Global Ophthalmic Equipment Market?

Market Dynamics

Drivers

  • Increasing geriatric population and rising cases of eye diseases
  • Increasing use of spectacles and contact lenses
  • Technological advancements in developing newer ophthalmic devices

Restraints

  • Costly and delicate devices

Opportunities

  • Government norms and initiatives to control visual impairment
  • Low adoption of phacoemulsification devices

Challenges

  • Lack of awareness about eye disorders and shortage of ophthalmologists

Companies Mentioned

  • Alcon Inc.
  • Bausch & Lomb Incorporated
  • Canon Medical Systems Corporation
  • Carl Zeiss Meditec AG
  • Diamatrix Ltd.,
  • Essilor International S.A.
  • Glaukos Corporation
  • Haag-Streit Holding
  • HEINE Optotechnik
  • Johnson & Johnson Private Limited
  • Luneau Technology Operations SAS
  • Nidek Co. Ltd.
  • Novartis AG
  • Ophtec B.V.
  • Ophtechnics Unlimited
  • Paramount Surgimed Ltd.
  • STAAR Surgical Company
  • Topcon Corporation
  • Unique Technologies, Inc.
  • Ziemer Ophthalmic Systems AG

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version